US Supreme Court Preview: ‘Skinny’ Labels, FTC, And FCA – But No Tecfidera As Biogen Loses Bid

Teva’s carve-out fight with GSK over generic Coreg will see the Solicitor General weigh in. Amgen and Juno’s patent petitions remain pending, and the high court stays a Federal Circuit decision invalidating Novartis’ Gilenya patent.

US Supreme Court interior
US Supreme Court opens term seeking Solicitor General's views in 'skinny label' case • Source: Shutterstock

More from Legal & IP

More from Pink Sheet